Use of a lipopeptide or lipoprotein as an adjuvant in therapeutic or prophylactic vaccinations
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Feb 2, 2021
Grant Date -
Sep 8, 2016
app pub date -
Mar 22, 2013
filing date -
Apr 4, 2002
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Disclosed is the use of lipopeptides and lipoproteins as mucosal adjuvants for various vaccinations via mucous membranes, particularly intranasally. Said lipopeptides represent peptides or proteins substituted with 2,3-diacyloxy(2R)-propyl at the amino-terminal cystein of a peptide or protein, preferably S-(2,3-bis-palmitoyloxy-(2R)-propyl)cysteinyl peptides derived from mycoplasmas. Said peptides are highly effective even in small doses, produce good immunization results, and increase the IgA level, among others.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully